23 slides from Arcticzymes Technologies Asa's earnings presentation, Aug 17, 2017
Slide 1: Q2 2017 Presentation
Q2 2017 Presentation 17.08.2017, Oslo
Slide 2: Agenda
Agenda • Highlights • Q2 Financials • BetaGlucans • Animal- and Consumer health • Cancer • Advanced wound care • Enzymes • Molecular research and diagnostics • Outlook 2
Slide 3: Highlights for Q2 2017
Highlights for Q2 2017 Tromsø • Solid quarter sales of NOK 16.4 mill (NOK 15.3 mill) • EBITDA of NOK -4.4 mill (NOK -1.6 mill) • Q2 Woulgan® sales NOK 0.9 mill • ArcticZymes sales of NOK 8.4 mill 8% above the good Q2 2016 3
Slide 4: Q2 Financials
Q2 Financials ites. BIOTEC ret” PHARMACON
Slide 5: Financial highlights Q2 2017
Financial highlights Q2 2017 NOK million Q2 2017 Q2 2016 6M 2017 6M 2016 Sales Enzymes 8.4 7.8 17.3 15.9 Sales BetaGlucans 8.0 7.5 17.3 16.6 Other revenues 1.4 1.7 3.0 3.6 Total revenues 17.8 17.0 37.6 36.1 Enzymes 2.6 3.0 5.2 5.6 BetaGlucans -4.6 -4.4 -9.3 -8.6 Corporate unallocated -2.3 -0.2 -4.4
Slide 6: Cash flow and cash position
Cash flow and cash position NOK million Q2 2017 Q2 2016 6M 2017 6M 2016 Operating activities -6.5 -3.0 -16.3 -13.7 Investing activities -1.5 0 -2.9 0 Financing activities 0 0 0 0 Changes in cash and cash equivalent -8.1 -3.0 -19.3 -13.7 Cash and cash equivalents at the 46.6 67.7 57.7 78.3 beginning
Slide 7: Beta-glucans
BIOTEC °° PHARMACON
Slide 8: Beta-glucans – segment numbers
Beta-glucans – segment numbers NOK million Q2 2017 Q2 2016 6M 2017 6M 2016 Sales Animal & Consumer Health 7.1 7.4 16.0 16.4 Sales Woulgan 0.9 0.1 1.3 0.2 Other revenues 0.7 0.5 1.3 1.0 Total revenues 8.7 8.1 18.6 17.6 Cost of Goods -4.3 -4.6 -10.2 -8.7 Personnel expenses -4.3 -4.5 -9.9 -10.1 Operati
Slide 9: Activities outside Woulgan®
Activities outside Woulgan® • Animal health sales experiences some seasonality • Consumer Health: • Product offering deemed to be attractive • Have generated several leads • Expect new customers on board in the following months • Participate in several trade shows e.g. Supply Side West, Las Vegas, e
Slide 10: Cancer adjuvant
Cancer adjuvant • About 140 patients treated with the vaccine/SBG combination at Memorial Sloan Kettering Cancer Center • Study increased from 145 to 185 patients • Biotec and MSKCC continue to discuss on how to move forward 10
Slide 11: Status Woulgan®
Status Woulgan® • Q2 in-market sales (consumption) more than trebled from Q1 to Q2 • Continue to invest resources into marketing and sales activities • Introduced online distributor trainings to increase sales productivity 11
Slide 12: Highlights Germany
Highlights Germany • More homecare companies adopt Woulgan® • Woulgan listed at Sangro Medical Service GmbH • Extended distribution agreement with Rogg Verbandstoffe • Completed “Expert Opinion” with 5 wound treatment centres and 28 patients • Will be presented at upcoming conferences in Germany 12
Slide 13: Highlights UK
Highlights UK •Appealed to UK Drug Tariff • Response expected in Q3 according to NHS’ own guidelines •Preparing a new contingency application that includes: • New UK evidence with German & Nordic case series 13
Slide 14: Highlights Nordics
Highlights Nordics • Positive feedback is slow to translate into sales due to delayed tender renewals • Norwegian wholesaler for community supply will shortly list Woulgan® • Case series recruitment progressing, now adding new Norwegian sites 14
Slide 15: Research and Development
Research and Development • Pilot plant for production of Woulgan® dry layer is being installed • Aim to develop proprietary methods for production that can be patent protected • Such gel-forming dry layer is well suited to more exuding- and larger surface wounds
Slide 16: ArcticZymes
ArcticZymes Molecular research and diagnostics
Slide 17: Enzymes – Segment Numbers
Enzymes – Segment Numbers NOK million Q2 2017 Q2 2016 6M 2017 6M 2016 Sales enzymes 8.4 7.8 17.3 15.9 Other revenues 0.8 1.2 1.7 2.6 Total revenues 9.2 9.0 19.0 18.5 Cost of goods 0 -0.1 0.3 -0.2 Personnel expenses -3.9 -3.9 -9.2 -9.1 Operating expenses -2.7 -2.0 -4.9 -3.6 EBITDA 2.6 3.0 5.2 5.6 Dep
Slide 18: Commercial Update
Commercial Update • Largest partner undergoing consolidation and centralisation of manufacturing to Europe • Likely to affect third quarter sales but with no longer-term effect • Supporting customer secures growing demand 18
Slide 19: SAN Portfolio Update
SAN Portfolio Update SAN High Quality (Bio-manufacturing Grade) Launched • SAN HQ is a more qualified version of the SAN enzyme • Meets strict requirement for utility in bio-manufacturing Salt Active Increasing Commercial Traction Nuclease • Launched SAN HQ at the ASGCT annual meeting – May 2017 Ove
Slide 20: IsoPol™ Polymerase Updates
IsoPol™ Polymerase Updates • Properties of our 2nd IsoPol™ enzyme are more optimal to several Next customer requests Generation Sequencing (NGS) • Anticipate launch of 2nd IsoPol™ enzyme before year-end. In customers hands during Q4 • LAMP isothermal amplification technologies is a highly-desirable
Slide 21: Outlook 2017
Outlook 2017 ‘ah - o@ete. BIOTEC ret” PHARMACON
Slide 22: Outlook 2017
Outlook 2017 • Commercial traction and sales in core markets for Woulgan® • Retain position in the Animal Health market with a modest growth • Building commercial platform in Consumer Health • Launch further products in ArcticZymes including Polymerases • Continue to widen ArcticZymes’ commercial pl
Slide 23: Contact
Contact: Barge Sgrvoll bso@biotec.no TIf: 95290187 www.biotec.no atest, BIOTEC ret” PHARMACON